MeMed

MeMed

Private
Haifa DistrictHealthcare & Life Scienceshttps://www.me-med.com

Last Round

VC Round

Jan 10, 2022

Total Funding Raised

$98.03M

Momentum Score

25 /100

Company Overview

MeMed is a healthcare technology company that develops immuno-personalized diagnostic devices to rapidly identify bacterial and viral infections by analyzing patients' immune responses, thereby assisting physicians in making informed antibiotic treatment decisions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

bacterial vs viral differentiationhost response diagnosticspoint-of-care diagnosticsPOC testingrapid diagnosticsantibiotic stewardshipantimicrobial resistanceAMRimmunoassayacute care diagnosticsprotein biomarkersin vitro diagnosticsIVDdiagnostic consumablesCOVID-19 severity test

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MeMed Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

MeMed Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 10, 2022
GrantNov 13, 2019
Series CSep 20, 2018
GrantFeb 6, 2018
GrantApr 19, 2017
Grant
Sep 18, 2015

Key People

Founding team and executive leadership

Kfir Oved

Member Of The Board Of Directors, Chairman, Co-founder, CTO, Board Member (Chariman 2016-2023)

Founding Team

Eran Eden

Co-founder CEO

Founding Team

Barak Hershkovitz

Chief Technology Officer. Israel Site Leader

Executive Team

Ariel Rubashkin

Chief Financial Officer

Executive Team

MeMed Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Developing a next-generation AIVD product.

  • Mar 1, 2026

    Diagnostic technology receives FDA clearance and is in use.

MeMed Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MeMed Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MeMed's valuation, stock price, and market status.

Firmographic Details

HeadquartersHaifa District
Employee Range97
Year Founded2009
Last FundingJan 10, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.